



# U.S. ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE

USAMRICD-TR-01-05

## Effects of Sodium 2-Mercaptoethanesulfonate (Mesna) as a Post-treatment in Mice Challenged with Phosgene

Jeffry S. Forster  
Steven I. Baskin  
Theodore S. Moran  
Mathew P. Cascio  
Traci L. Graham  
Alfred M. Sciuto

May 2001

20011022 013

Approved for public release; distribution unlimited

U.S. Army Medical Research  
Institute of Chemical Defense  
Aberdeen Proving Ground, MD 21010-5400

#### DISPOSITION INSTRUCTIONS:

Destroy this report when no longer needed. Do not return to the originator.

#### DISCLAIMERS:

The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Army or the Department of Defense.

In conducting the research described in this report, the investigators adhered to the *Guide for the Care and Use of Laboratory Animals* by the Institute of Laboratory Animal Resources, National Research Council, in accordance with the stipulations mandated for an AAALAC accredited facility.

The use of trade names does not constitute an official endorsement or approval of the use of such commercial hardware or software. This document may not be cited for purposes of advertisement.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) May 2001		2. REPORT TYPE Technical Report		3. DATES COVERED (From - To) 10 November 98 to 12 January 2000	
4. TITLE AND SUBTITLE Effects of Sodium 2-Mercaptoethanesulfonate (Mesna) as a Post-treatment in Mice Challenged with Phosgene				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER 63384	
				5d. PROJECT NUMBER TC3	
6. AUTHOR(S) Jeffry S. Forster, Steven I. Baskin, Theodore S. Moran, Mathew P. Cascio, Traci L. Graham, Alfred M. Sciuto				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
				8. PERFORMING ORGANIZATION REPORT NUMBER USAMRICD-TR-01-05	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) US Army Medical Research Institute of Chemical Defense ATTN: MCMR-UV-PN 3100 Ricketts Point Road Aberdeen Proving Ground, MD 21010-5400				10. SPONSOR/MONITOR'S ACRONYM(S)	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) US Army Medical Research Institute of Chemical Defense ATTN: MCMR-UV-RC 3100 Ricketts Point Road Aberdeen Proving Ground, MD 21010-5400				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The effects of 2-mercaptoethanesulfonate (mesna) as a post-treatment against exposure to a lethal dose of phosgene (CG) were investigated. Mesna appears to be a potential candidate against phosgene-induced injury because it may increase sulfhydryl concentrations, which may reduce cellular injury. Mice were exposed to phosgene, 32 mg/m <sup>3</sup> , or air for 20 minutes. After a 5-minute washout with air, mice were injected interperitoneally (ip) with 0, 334, 834 or 1,667 mg/kg of mesna or phosphate buffered saline (PBS) at 20 minutes, 2, 5, 8 and 11 hours. Survival was assessed every 2 hours for 12 hours and at 24 hours. Lungs were removed and analyzed for wet weight, dry weight, wet/dry ratio, protein, and non-protein sulfhydryls (NPSH). These parameters were measured up to 12 hours after exposure. Air-exposed mice (treated equivalently) were also sacrificed. Survival rates were increased in the 834 mg/kg mesna + CG group through eight hours over the PBS + CG group. Only at the 8-hour time point did the 1,667 mg/kg mesna + CG dose show an increase in survival rates compared with PBS + CG control. Wet weight, dry weight, and wet/dry ratio were not statistically different from CG + PBS controls for all groups. Non-protein sulfhydryls did, however, show an increase at the 1,667 mg/kg dose at the 12-hour time point. These data suggest that in this paradigm, thiols only play a minor role in phosgene toxicity. In conclusion, while mesna shows some degree of protection against CG, the large doses required to afford this protection may offer only a narrow dose range window of therapeutic opportunity for the treatment of phosgene.					
15. SUBJECT TERMS Mesna, 2-Mercaptoethanesulfonate, Phosgene, Lung Edema					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT  UNLIMITED	18. NUMBER OF PAGES  16	19a. NAME OF RESPONSIBLE PERSON Jeffry S. Forster
a. REPORT UNCLASSIFIED	b. ABSTRACT UNCLASSIFIED	c. THIS PAGE UNCLASSIFIED			19b. TELEPHONE NUMBER (include area code) 410-436-5116

## Introduction

2-Mercaptoethanesulfonate (mesna) (Mesnex<sup>®</sup>) (Figure 1) is used clinically, most notably as an adjunct in cancer chemotherapy.<sup>1,2</sup> Mesna, by virtue of its thiol group, appears to bind to and detoxify various metabolites of chemotherapeutic drugs, rendering them harmless and allowing the body to excrete them without damage.<sup>3</sup> Also known as Uromitexan<sup>®</sup>, mesna appears to reduce the viscosity of mucus, aiding mucociliary clearance<sup>1</sup> and may have antioxidant properties.<sup>4,5</sup> Mesna may also increase levels of glutathione (GSH) (Figure 2), a water-soluble thiol. It is this thiol-containing tripeptide and its ability to form conjugates with toxic chemicals that make GSH important in protecting cells against reactive O<sub>2</sub> and free radicals.<sup>6</sup> GSH also protects proteins by preventing oxidation of SH groups and by reducing disulfide bonds caused by oxidative stress.<sup>7</sup>

Phosgene (CG) is a toxic gas that was used extensively in World War I resulting in vast numbers of injuries and deaths. Today it is used in the synthesis of insecticides, plastics, pharmaceutical drugs and dyes.<sup>8</sup> The National Institute for Occupational Safety and Health (NIOSH) reports that over one million tons of phosgene are produced annually in the United States and that thousands of workers may be involved with its production and usage.<sup>9</sup> CG is usually completely consumed in most of these processes; however, an accident or spill could lead to serious medical and occupational problems for industrial workers or firefighters. Inhalation of CG can cause non-cardiogenic pulmonary edema and possibly death, within 6-24 hours after exposure.<sup>10</sup> In this study we evaluated the therapeutic efficacy of a post-exposure administration of mesna against a toxic concentration of CG. We measured survival ratios every two hours for 12 hours and at 24 hours. Non-protein sulfhydryls were measured also as an indication of protective thiol groups.

## Methods

Male CD-1 (Charles River, Wilmington, MA) mice weighing 25-30g were exposed whole-body to 32 mg/m<sup>3</sup> phosgene for 20 min (640 mg·min/m<sup>3</sup>). All elements of exposure were performed in an approved laboratory fume hood. Ten percent phosgene:balance N<sub>2</sub> (Matheson Gas Products, Baltimore, MD) was metered through a Tylan mass flow controller (Tylan Corp., Torrance, CA) at a rate of 20 L/min. This was mixed with room air and then passed through an infrared spectrometer (Miran 1A, Foxboro Co., Sharon, MA). The Miran 1A was equipped with a real-time analog output. Concentration versus time graphs were developed, and the input concentration was calculated. The exposure occurred in a Plexiglas cylinder (25 cm in height x 28 cm in diameter) with a total volume of 15.8 L. The chamber was divided into 4 quadrants with 10 mice per quadrant. Exposure to phosgene was for 20 minutes followed by a 5-minute chamber air washout. Outflowing gas from the chamber was passed through a second Miran 1A unit to determine the concentration of phosgene exiting the chamber. Following the exposure, the mice were injected (IP) with appropriate mesna (334, 834 or 1,667 mg/kg) or PBS treatments at 20 minutes, 2, 5, 8 and 11 hours after being removed from the chamber, to maintain a constant level of mesna. In all, each mouse received 5 injections of the appropriate concentration of mesna. Mesna was prepared fresh in PBS

the day of the experiment and each injection consisted of 0.5 ml of solution. Mice were exposed in two groups of 40, one group receiving phosgene and the other group receiving air. This regimen was performed on three separate occasions. Number of mice and how they were grouped are in Table 1 below.

**Table 1**

<b>Mesna (mg/kg)</b>	<b>AIR</b>	<b>CG</b>
0 (PBS)	42	42
334	13	13
834	39	39
1667	26	26

Mice were observed for 12 hours from the end of exposure. Mice that expired within 12 hours were weighed immediately and necropsied for their lung tissue. The left lung was weighed and placed on a tared planchette for wet/dry weight ratios. Lungs for the wet/dry ratio were placed in an oven at 100°C and reweighed eight days later for dry weight. The entire right lung was quickly frozen in liquid nitrogen and stored at -80°C for future biochemical measurements. All lung weight gravimetric data are from mice that expired at 12 hours after the start of exposure. There are no gravimetric parameters or NPSH data from lung tissue of mice that died after 12 hours because these tissues were not fresh.

Since the mass of individual mouse lungs was small, we pooled lung tissue within the same drug treatment groups. Three to four mouse lungs were pooled for each treatment dose per assay since this enabled us to adequately perform assays in duplicate. All assays were performed on pooled mouse lung tissue, which was ground to a fine powder under liquid nitrogen.

As an estimate of protective thiol concentrations, nonprotein bound sulfhydryls were measured using the method outlined by Sedlak and Lindsay.<sup>11</sup> Briefly, 75 mg of pooled frozen lung tissue was homogenized in 0.02 M EDTA disodium salt and mixed with distilled water and 15% TCA. Next, these homogenates were mixed with 0.4 M tris buffer and 0.2 M EDTA disodium salt, pH 8.9, and 100 µl of dithio-bis-[2-nitrobenzoic acid] (DTNB) and slowly shaken at room temperature for 15 minutes. This solution was then centrifuged at 3000 x g for 15 minutes. Absorbance values of supernatants were recorded at 412 nm using a UV-VIS spectrophotometer. NPSH concentration was calculated using the published molar extinction coefficient of  $13.1 \times 10^5 \text{ M}^{-1}\text{cm}^{-1}$ .<sup>11</sup> Fifty mg of pooled lung tissue was analyzed for tissue protein concentration by the method of Lowry and co-workers.<sup>12</sup> Nonprotein sulfhydryls were standardized using lung tissue protein concentrations.

Comparisons of lung weight parameters or tissue biochemical measurements between exposed drug-treated mice and exposed PBS-treated mice were analyzed by a one-way ANOVA. If significant, the ANOVA was followed by a Newman-Keuls post hoc multiple comparison test. Survival was statistically evaluated using Chi square ( $\chi^2$ ) distribution. Calculations of odds ratios for survival were performed according to Kahn.<sup>13</sup> Data were considered statistically different at a significance level of  $p \leq .05$ .

## Results

In this set of experiments all air exposed, mesna-treated mice survived for 24 hours. We did see an increase in survival rates in mice that received phosgene and were post-treated with mesna. Survival rates were significantly increased in the 834 mg/kg mesna + CG group over the CG + PBS group in each two-hour time segment starting at the four-hour time point and going through 8 hours,  $p \leq .05$ . In contrast, the 1,667 mg/kg mesna + CG group showed an increase in survival rate over the CG + PBS group only at the 8-hour time point,  $p \leq .05$  (Figure 3).

Lung wet weight is an indication of the amount of edema produced in the lung. In our experiment, lung wet weight was significantly increased in phosgene-exposed mice compared with air-exposed mice (Figure 4); in some cases it was 2 to 3 times that of the air-exposed mice at the 12-hour time point. Even in mesna-treated mice at all concentrations, lung wet weight was not reduced enough to approach air-exposed mice. There does, however, appear to be a downward trend after the 334 mg/kg mesna dose in the lung wet weight. In fact, in this gravimetric assessment, the 1,667 mg/kg dose of mesna, when given to CG-exposed mice, significantly reduced the lung wet weight over that of the other doses of mesna.

The existence of pulmonary edema increases the proportion of packed red blood cells to plasma ratio and is a further indication of a severe lung fluid imbalance. Lungs taken from CG mice take on a hemorrhagic appearance and, because of the packed red blood cell hyperaggregation, may have increased dry weights. We dried both air-exposed and CG-exposed lungs for eight days and assessed the differences in their weights as an indication of lung damage (Figure 5). Lung dry weights for CG-exposed mice were significantly higher at all mesna concentrations than that of air-exposed mice at the 12-hour time point. In fact, they were almost double that of air-exposed mice regardless of the concentration of mesna. However, the lung dry weights of 1,667 mg/kg mesna + CG mice were significantly lower than that of the other mesna-treated mice or that of the PBS + CG mice. We saw the same phenomena in the wet weight to dry weight ratio (Figure 6). Wet/dry weight ratios for CG-exposed mice were three times that of air-exposed animals regardless of the mesna concentrations at the 12-hour time point. However, again at the 1,667 mg/kg mesna concentration, the wet/dry weight ratios were significantly reduced compared with other mesna-treated or PBS-treated CG-exposed mice.

Thiol status in the lung was determined by measuring lung tissue nonprotein-bound sulfhydryls. While there appears to be a small trend upward in the mesna + CG mice, the NPSH are not significantly increased over air-exposed mice for the three lower concentrations of mesna. However, in mice receiving 1,667 mg/kg of mesna + CG, there was a significant increase in NPSH over air-exposed mice (Figure 7).



## Discussion

Phosgene is capable of widespread tissue destruction and cell death as well as reducing thiol containing glutathione levels in lung tissue.<sup>14,15</sup> In an attempt to increase survival rates of mice exposed to phosgene, we treated exposed mice with mesna (ip), a drug that has been shown to aid mucociliary clearance<sup>1</sup> and to have antioxidant properties.<sup>4,5</sup> We used large doses of mesna, 334, 834 and 1,667 mg/kg (the LD<sub>50</sub> for mice is about 2,230 mg/kg, sc),<sup>16</sup> since we wanted to stay just below the LD<sub>50</sub>. When we increased the dose of mesna to 3,334 mg/kg, 75% of the air-exposed mice died within 90 minutes (data not shown). At the concentrations of mesna that we used in this experiment (334, 834 and 1,667 mg/kg), mesna had little or no effect on air-exposed mice. Ormstad<sup>3</sup> found that after ip injections of mesna in rats, the plasma levels of free thiol groups were greatly reduced within the first hour after injection. For this reason, we injected the mice multiple times (five in all) to try to maintain constant levels of free thiols. Since the mice were getting the mesna in 0.5 ml injections, we wanted to space the injection times to allow the animals to absorb the liquid. Since we could not predict when the mice would die from the exposure to phosgene, some of the mice were injected just prior to death, whereas others died an hour or more after being injected.

Mesna, while increasing glutathione concentrations, may also increase intracellular levels of cysteine.<sup>17</sup> Lauterburg<sup>17</sup> saw only a transient rise of GSH as he combined mesna with ifosfamide, an alkylating chemotherapeutic drug. Mesna combines with ifosfamide metabolites detoxifying them, but rendering mesna unable to convert GSSG to GSH. Since we did not use mesna in combination with any other drugs we hoped to see a constant increase in GSH, and because mesna is also a mucolytic agent and has shown antioxidant properties,<sup>4</sup> we thought it to be a good candidate drug to protect against a phosgene challenge. We realized that the doses of mesna were very large and probably not realistic for use in the field; however, determination of survival rates was the main reason for this set of experiments.

Mesna did statistically increase survivability through 8 hours at the 834 mg/kg concentration, and although more mice given CG + mesna survived after 8 hours than did mice given CG + PBS, there was no statistical difference between the two groups. As mentioned above, Lauterburg also saw an increase in cysteine levels. This rise in cysteine may have led to cysteine toxicity and as a result caused increased mortality. In fact, Olney saw that giving L-cysteine sc, 1, 2 and 3 mg/g to 8- to 10-day-old mice can be lethal.<sup>18</sup> It is also known that cysteine may be spontaneously oxidized to cysteine disulfide and H<sub>2</sub>O<sub>2</sub>, causing damage to cell membranes.<sup>19</sup> We may have been at a critical level of mesna where the 834 mg/kg dose was beneficial to mice and the 1,667 mg/kg dose was enough to cause too great a rise in cysteine, too much for the liver to detoxify. It could be possible that the increase in cysteine caused by mesna may have been too much for an already compromised animal to endure.

Phosgene has been shown to increase TNF-production from macrophages,<sup>20</sup> compromise the immune system and cause lung infection,<sup>21</sup> increase plasma iron,<sup>22</sup> and increase arachidonic acid mediators;<sup>23</sup> therefore, many obstacles would have to be overcome to increase survival due to phosgene exposure. Sciuto *et al.*<sup>24</sup> found that an intratracheal administration of N-acetylcysteine after exposure to phosgene elevated GSH levels in rabbits. Sciuto also found that N-acetylcysteine prevented edema formation,


peptide leukotrine production and lipid peroxidation in rabbits. Our group administered N-acetylcysteine interperitoneally (ip) to mice after exposure to phosgene and saw little GSH elevation (data not shown). Could this phenomenon be due to the route of administration, intratracheal vs ip? It would appear that delivering a drug directly to the site of injury would be beneficial as opposed to administering the drug to another site. Could our lack of GSH elevation be due to our use of a different species? In much the same vein, would mesna benefit from a different route of administration? It would appear that raising GSH levels is not enough to ensure survival.

In conclusion, although mesna conveys increased survivability through 8 hours, there is insufficient evidence of overall improved outcome at these concentrations with its use in the treatment of CG exposure using this paradigm.







**Figure 1.** Structure of Mesna




**Figure 2.** Structure of GSH




**Figure 3.** Survival rates for varying concentrations of mesna.




**Figure 4.** Lung wet weight at 12 hours.



**Figure 5.** Dry weights for lungs exposed to phosgene and air at 12 hours.



**Figure 6.** Lung wet weight divided by dry weight.



**Figure 7.** Non-protein sulfhydryls corrected for protein.

## References

1. Shaw IC, Graham MI: Mesna-a short review. *Cancer Treatment Reviews* 1987;14:67-86.
2. Schoenike SE, Dana WJ: Ifosfamide and mesna. *Clinical Pharmacy* 1990;9:179-191.
3. Ormstad K, Orrenius S, Låstbom T, Uehara N, Pohl J, Stekar J, Brock N: Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat. *Cancer Research* 1983;43:333-338.
4. Gressier B, Lebegue S, Brunet C, Dine C, Luyckx M, Cazin M: The effect of mesna in reversing *in vitro*, the protease-antiprotease imbalance: its reaction on the MPO-H2O2 system and on human leukocyte elastase. *International Journal of Pharmaceutics* 1994;104:151-156.
5. Cabanis A, Gressier B, Lebegue S, Dine T, Brunet C, Luyckx M: Effects in vitro of mesna on the production of some reactive oxygen species by human neutrophils. *Pharm. Pharmacol. Lett.* 1993;2:236-239.
6. Reed D: Review of the current status of calcium and thiols in cellular injury. *Chem. Res. Toxicol.* 1990;3:495-502.
7. Lu S: Regulation of hepatic glutathione synthesis: current concepts and controversies. *The FASEB Journal* 1999;13:1169-1183.
8. Babad H, Aeiler AG: The chemistry of phosgene. *Chem. Rev.* 1973;1:75-91
9. National Institute for Occupational Health and Safety. 1976 Criteria for a recommended standard: occupational exposure to phosgene. Department of Health, Education, and Welfare, Public Health Service, CDC publication 76137. Washington, DC.
10. Diller WF: Medical problems and their solutions. *J. Occup. Med.* 1978;20(3):189-193.
11. Sedlak J, Lindsay R: Estimation of total, protein bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. *Anal. Biochem.* 1968;25:192-205.
12. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with folin phenol reagent. *J. Biol. Chem.* 1951;193:265-275
13. Kahn HA: *Introduction to Epidemiologic Methods*. New York: Oxford University Press. 1983.
14. Currie, WD, Hatch GE, Frosolono MF: Changes in lung ATP concentration in the rat after low-level phosgene exposure. *J. Biochem. Toxicol.* 1987;2:105-114.
15. Sciuto AM: Ibuprofen treatment enhances the survival of mice following exposure to phosgene. *Inhalation Toxicology* 1997;9:389-403.
16. Mitsuzono, T, Homoku, K, Kogawa, M, Ishimura, K Harada: Acute toxicity studies of mesna in mice, rats and dogs. *Kiso To Rinsho* 1991;25:5-17.
17. Lauterburg B, Nguyen T, Hartmann B, Junker E, Küpfer A, Cerny T: Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. *Cancer Chemother. Pharmacol.* 1994;35:132-136.
18. Olney, JW, Ho, OL, Rhee, V, Schainker, B: Cysteine-induced brain damage in Infant and Fetal Rodents. *Brain Research* 1972;45:309-313.
19. Harrison, DC, Thurlow, S: Secondary oxidation of some substances of physiological interest. *Biochem Journal* 1926;20:218.

20. Deshpande, A, Archuleta, YE, Valdez, NM, Stavert, DM, Lehnert, BE: Tumor necrosis factor- $\alpha$  production by alveolar macrophages during the early development of phosgene-induced lung injury. *Inhalation Toxicology* 1996;8:65-80.
21. Burleson, GR, Keys, LL: Natural killer activity in Fischer-344 rat lungs as a method to assess pulmonary immunocompetence: Immunosuppression by phosgene inhalation. *Immunopharmacology and Immunotoxicology* 1989;11:421-443.
22. Kennedy, TP, Rao, NV, Noah, W, Michael, JR, Jafri, MH, Gurtner, GH, Hoidal, JR: Ibuprofen prevents oxidant lung injury and *in vitro* lipid peroxidation by chelating iron. *J. Clin. Invest.* 1990;86:1565-1573.
23. Guo, YL, Kennedy, TP, Michael, JR, Sciuto, AM, Ghio, AJ, Adkinson, JR, Gurtner, GH: Mechanism of phosgene-induced lung toxicity: Role of arachidonate mediators. *J. Appl. Physiol.* 1990;69:1615-1622.
24. Sciuto, AM, Strickland, PT, Kennedy, TP, Gurtner, GH: Protective effects of N-acetylcysteine treatment after phosgene exposure in rabbits. *Am. J. Respir. Crit. Care Med.* 1995;151:768-72.

## DISTRIBUTION LIST

Addresses	Copies	Addresses	Copies
DEFENSE TECHNICAL INFORMATION CENTER ATTN DTIC OCP 8725 JOHN J KINGMAN RD STE 0944 FT BELVOIR VA 22060-6218	1	DIRECTOR ARMED FORCES MEDICAL INTELLIGENCE CENTER 1607 PORTER STREET FORT DETRICK MD 21702-5004	1
COMMANDER US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND ATTN MCMR PLD 504 SCOTT ST FORT DETRICK MD 21702-5012	2	COMMANDER US ARMY INSTITUTE OF DENTAL RESEARCH BUILDING 40 WASHINGTON DC 20307-5300	1
HQDA OFFICE OF THE SURGEON GENERAL 5109 LEESBURG PIKE SUITE 691 FALLS CHURCH VA 22041-3258	1	COMMANDER US ARMY INSTITUTE OF SURGICAL RESEARCH BUILDING 2653 FORT SAM HOUSTON TX 78234-6200	1
DIRECTOR WALTER REED ARMY INSTITUTE OF RESEARCH ATTN MCMR UWZ L 503 ROBERT GRANT AVENUE SILVER SPRING MD 20910-7500	1	COMMANDER USAMEDD CENTER & SCHOOL ATTN MCCS FC FORT SAM HOUSTON TX 78234-6100	1
COMMANDER US ARMY AEROMEDICAL RESEARCH LABORATORY ATTN SCIENTIFIC INFORMATION CENTER PO BOX 577 FORT RUCKER AL 36362-5000	1	COMMANDER USAMEDD CENTER & SCHOOL ATTN MCCS FCD FORT SAM HOUSTON TX 78234-6100	1
COMMANDER US ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES 1425 PORTER ST FORT DETRICK MD 21702-5011	1	DIRECTOR ENVIRONMENTAL AND LIFE SCIENCES OFFICE OF THE DEPUTY DIRECTOR FOR RESEARCH AND ENGINEERING ROOM 3D129 WASHINGTON DC 20301-2300	1
COMMANDER US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE ATTN MCMR UE ZS (MS SAFRAN) BUILDING 42 NATICK MA 01760-5007	1	COMMANDER US ARMY TRAINING AND DOCTRINE COMMAND ATTN ATMD FORT MONROE VA 23651	1
COMMANDANT US ARMY CHEMICAL SCHOOL ATTN ATZN CM C FORT MCCLELLAN AL 36205	1	COMMANDER US ARMY NUCLEAR AND CHEMICAL AGENCY 7500 BACKLICK ROAD BUILDING 2073 SPRINGFIELD VA 22150-3198	1



COMMANDER US ARMY MEDICAL MATERIEL DEVELOPMENT ACTIVITY ATTN MCMR UMD 622 NEIMAN ST FORT DETRICK MD 21702-5009	1	AFOSR/NL BUILDING RM A217 BOLLING AFB DC 20332	1
EXECUTIVE OFFICER NAVAL MEDICAL RESEARCH INSTITUTE NAVAL MEDICINE COMMAND NATIONAL CAPITAL REGION BETHESDA MD 20814	1	COMMANDER US ARMY EDGEWOOD CHEMICAL AND BIOLOGICAL CENTER TECHNICAL LIBRARY ATTN AMSSB RC I (E3330) E5183 BLACKHAWK ROAD ABERDEEN PROVING GROUND MD 21010-5424	1
DEPARTMENT OF THE NAVY NAVAL POSTGRADUATE SCHOOL DUDLEY KNOX LIBRARY 411 DYER ROAD ROOM 110 MONTEREY CA 93943-5101	1	COMMANDER US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE 3100 RICKETTS POINT ROAD ATTN MCMR UV ZA MCMR UV ZB MCMR UV ZS MCMR UV RC (5 copies) MCMR UV R (11 copies) MCMR UV AI W MCMR UV D MCMR UV P MCMR UV C ABERDEEN PROVING GROUND MD 21010-5425	23
USAF ARMSTRONG LABORATORY/CFTO SUSTAINED OPERATIONS BRANCH BROOKS AFB TX 78235-5000	1		
DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH THE NATIONAL LIBRARY OF MEDICINE SERIAL RECORDS SECTION 8600 ROCKVILLE PIKE BETHESDA MD 20894	1		
STEMSON LIBRARY ACADEMY OF HEALTH SCIENCES BUILDING 2840 RM 106 FORT SAM HOUSTON TX 78234-6100	1		
US ARMY RESEARCH OFFICE ATTN CHEMICAL AND BIOLOGICAL SCIENCES DIVISION PO BOX 12211 RESEARCH TRIANGLE PARK NC 27709-2211	1		